BIIB vs. CI: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BIIB and CI, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BIIB | CI |
|---|---|---|
| Company Name | Biogen Inc. | The Cigna Group |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 22.61 billion USD | 77.85 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | September 17, 1991 | March 31, 1982 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BIIB and CI by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BIIB | CI |
|---|---|---|
| 5-Day Price Return | 13.67% | 2.67% |
| 13-Week Price Return | 18.57% | -12.78% |
| 26-Week Price Return | 9.90% | -10.19% |
| 52-Week Price Return | -20.44% | -15.82% |
| Month-to-Date Return | 10.09% | 1.18% |
| Year-to-Date Return | 0.85% | 5.62% |
| 10-Day Avg. Volume | 1.88M | 1.56M |
| 3-Month Avg. Volume | 1.50M | 1.76M |
| 3-Month Volatility | 37.29% | 29.17% |
| Beta | 0.11 | 0.29 |
Profitability
Return on Equity (TTM)
BIIB
9.04%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
BIIB’s Return on Equity of 9.04% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
CI
12.27%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
CI’s Return on Equity of 12.27% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BIIB
15.31%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
BIIB’s Net Profit Margin of 15.31% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
CI
1.92%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
CI’s Net Profit Margin of 1.92% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
BIIB
20.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
BIIB’s Operating Profit Margin of 20.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
CI
3.41%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
CI’s Operating Profit Margin of 3.41% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BIIB | CI |
|---|---|---|
| Return on Equity (TTM) | 9.04% | 12.27% |
| Return on Assets (TTM) | 5.43% | 3.26% |
| Net Profit Margin (TTM) | 15.31% | 1.92% |
| Operating Profit Margin (TTM) | 20.80% | 3.41% |
| Gross Profit Margin (TTM) | 75.43% | 9.86% |
Financial Strength
Current Ratio (MRQ)
BIIB
2.50
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
BIIB’s Current Ratio of 2.50 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
CI
0.79
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
CI’s Current Ratio of 0.79 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BIIB
0.36
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
BIIB’s Debt-to-Equity Ratio of 0.36 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
CI
0.77
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
CI’s Debt-to-Equity Ratio of 0.77 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BIIB
4.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
BIIB’s Interest Coverage Ratio of 4.35 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
CI
2.32
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
CI’s Interest Coverage Ratio of 2.32 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BIIB | CI |
|---|---|---|
| Current Ratio (MRQ) | 2.50 | 0.79 |
| Quick Ratio (MRQ) | 1.79 | 0.68 |
| Debt-to-Equity Ratio (MRQ) | 0.36 | 0.77 |
| Interest Coverage Ratio (TTM) | 4.35 | 2.32 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
CI
2.06%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Yield of 2.06% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
CI
31.63%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Payout Ratio of 31.63% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | BIIB | CI |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.06% |
| Dividend Payout Ratio (TTM) | 0.00% | 31.63% |
Valuation
Price-to-Earnings Ratio (TTM)
BIIB
14.44
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
In the lower quartile for the Biotechnology industry, BIIB’s P/E Ratio of 14.44 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
CI
15.34
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
CI’s P/E Ratio of 15.34 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BIIB
2.21
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, BIIB’s P/S Ratio of 2.21 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
CI
0.29
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
CI’s P/S Ratio of 0.29 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
BIIB
1.04
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
BIIB’s P/B Ratio of 1.04 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
CI
2.20
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
CI’s P/B Ratio of 2.20 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BIIB | CI |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 14.44 | 15.34 |
| Price-to-Sales Ratio (TTM) | 2.21 | 0.29 |
| Price-to-Book Ratio (MRQ) | 1.04 | 2.20 |
| Price-to-Free Cash Flow Ratio (TTM) | 11.97 | 11.90 |